All In Biotech

Drug Trial Radar · NCT07170917

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 208 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

208

Planned (sponsor's estimate)

Start

Nov 6, 2025

Primary completion

Feb 9, 2027

Study completion Nov 23, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 164 weeks for participants transitioning into the long-term extension (LTE) period and will be up to approximately 60 weeks for participants not transitioning into the LTE period. The randomized treatment duration will be up to approximately 152 weeks

Conditions

  • Hidradenitis Suppurativa

Interventions

  • BrivekimigDrug

    * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection

  • PlaceboDrug

    * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: Up to Week 16

Locations

85 sites in 19 countries. Site status is shown where the registry gives one.

  • Medical Dermatology Specialists- Site Number : 8400019

    Phoenix, Arizona · Recruiting

  • Mayo Clinic in Arizona - Scottsdale- Site Number : 8400014

    Scottsdale, Arizona · Recruiting

  • Northridge Clinical Trials - Northridge- Site Number : 8400005

    Northridge, California · Recruiting

  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8400001

    Fort Myers, Florida · Recruiting

  • FXM Clinical Research - Miami- Site Number : 8400017

    Miami, Florida · Recruiting

  • FXM Clinical Research - Miramar- Site Number : 8400004

    Miramar, Florida · Recruiting

  • Advanced Medical Research - Atlanta- Site Number : 8400011

    Atlanta, Georgia · Recruiting

  • Georgia Skin & Cancer Clinic- Site Number : 8400009

    Savannah, Georgia · Recruiting

  • The Iowa Clinic West Des Moines Campus- Site Number : 8400007

    West Des Moines, Iowa · Recruiting

  • Louisiana Dermatology Associates- Site Number : 8400006

    Baton Rouge, Louisiana · Recruiting

  • Washington University- Site Number : 8400010

    St Louis, Missouri · Recruiting

  • JDR Dermatology Research- Site Number : 8400012

    Las Vegas, Nevada · Recruiting

  • Icahn School of Medicine at Mount Sinai- Site Number : 8400021

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill- Site Number : 8400025

    Chapel Hill, North Carolina · Recruiting

  • Clinical Partners- Site Number : 8400002

    Johnston, Rhode Island · Recruiting

  • AMR Clinical South Strand, South Carolina- Site Number : 8400018

    Myrtle Beach, South Carolina · Recruiting

  • Ut Southwestern Medical Center, Department Of Dermatology- Site Number : 8400022

    Dallas, Texas · Recruiting

  • Investigational Site Number : 0360003

    Liverpool, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360002

    Melbourne, Victoria, Australia · Recruiting

  • Investigational Site Number : 1240008

    Edmonton, Alberta, Canada · Recruiting

  • Investigational Site Number : 1240007

    Sherwood Park, Alberta, Canada · Recruiting

  • Investigational Site Number : 1240003

    Kelowna, British Columbia, Canada · Recruiting

  • Investigational Site Number : 1240001

    Hamilton, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240009

    Toronto, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240005

    Québec, Quebec, Canada · Recruiting

  • Investigational Site Number : 1520004

    Talcahuano, Biobio, Chile · Recruiting

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1520005

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Investigational Site Number : 1560002

    Chengdu, China · Recruiting

  • Investigational Site Number : 1560001

    Guangzhou, China · Recruiting

  • Investigational Site Number : 1560004

    Shanghai, China · Recruiting

  • Investigational Site Number : 1560005

    Ürümqi, China · Recruiting

  • Investigational Site Number : 2030002

    Ostrava, Czechia · Active not recruiting

  • Investigational Site Number : 2030003

    Ostrava, Czechia · Active not recruiting

  • Investigational Site Number : 2030001

    Prague, Czechia · Active not recruiting

  • Investigational Site Number : 2030004

    Prague, Czechia · Active not recruiting

  • Investigational Site Number : 2500001

    Antony, France · Recruiting

  • Investigational Site Number : 2500004

    Bezannes, France · Recruiting

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.